2Szajewska H, Sk6rka A, Dylag M. Meta-analysis: Saccha- romyces boulardii for treating acute diarrhoea in children[J]. Aliment Pharmaeol Ther, 2007, 25(3):257-264.
3Htwe K, Yee KS, Tin M, et al. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study[J]. Am J Trop Med Hyg, 2008, 78(2):214-216.
4Zanello G, Meurens F, Berri M, Salmon H. Saccharomyces boulardii effects on gastrointestinal diseases[J]. Curr Issues Mol Biol, 2009, 11(1):47-58.
5Buts JP, Dekeyser N, Stilmant C, et al. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation[J]. Pediatr Res, 2006, 60(1):24-29.
6Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression[J]. Biochem Biophys Res Commun, 2006, 343(1): 69-76.
7Mumy KL, Chen X, Kelly CP, et al. Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 294(3):G599-G609.
8Ozkan TB, Sahin E, Erdemir G, et al. Effect of Saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune response[J]. J Int Med Res, 2007, 35(2):201-212.
6Zaman K, Dang DA,Victor JC, et al. Efficacy of pentavalent rotavir- us vaccine against severe rotavirus gastroenteritis in infants in develo- ping countries in Asia: a randomised, double-blind, placebo-con- trolled trialFJ]. Lancet 2010"- 376:615 - 623.
7Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double- blind, placebo-controlled trial[ J]. Lancet ,2010,376 : 606-614.
